Aduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual Meeting
November 01 2017 - 9:05AM
Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with
three distinct immunotherapy technologies, today announced
preclinical data presentations relating to BION-1301, the company’s
anti-APRIL targeting B-select monoclonal antibody, to be given at
the 59th American Society of Hematology (ASH) Annual Meeting and
Exposition taking place in Atlanta, Georgia, December 9-12,
2017.
Accepted for Oral Presentation
Abstract 499: A First in Class APRIL Fully Blocking
Antibody Targets Novel Immune Regulation of APRIL in Multiple
Myeloma: Further Therapeutic Implication
- Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical
Studies, excluding Therapy: Novel Immunotherapeutic Strategies in
Multiple Myeloma
- Session Date: Sunday, December 10, 2017
- Session Presentation Time: 4:30 p.m. EST
- Room: Georgia World Congress Center, Building B, Level 3,
B308-B309
Accepted for Poster Presentation
Abstract 1827: BION-1301, a First-in-Class APRIL
Neutralizing Antibody for the Treatment of Multiple Myeloma:
Preclinical Safety, and Analysis of Pharmacokinetics -
Pharmacodynamics Relationship
- Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical
Studies, excluding Therapy: Novel Immunotherapeutic Strategies in
Multiple Myeloma
- Session Date: Sunday, December 10, 2017
- Session Viewing Time: 9:00 a.m. – 8:00 p.m.
EST
- Session Presentation Time: 6:00 p.m. – 8:00 p.m. EST
- Room: Georgia World Congress Center, Building B, Level 3,
B308-B309
To view these abstracts, please visit the ASH website located at
http://www.hematology.org/Annual-Meeting/.
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's LADD technology
platform is based on proprietary attenuated strains of Listeria
that have been engineered to express tumor-associated antigens to
induce specific and targeted immune responses. This platform is
being developed as a treatment for multiple indications, including
mesothelioma, gastric, ovarian, lung and prostate cancers.
Additionally, a personalized form of LADD, or pLADD, is in Phase 1
development utilizing tumor neoantigens that are specific to an
individual patient’s tumor. Aduro's STING Pathway Activator
platform is designed to activate the STING receptor in immune
cells, resulting in a potent tumor-specific immune response.
ADU-S100 is the first STING Pathway Activator compound to enter the
clinic and is currently being evaluated in both a Phase 1
monotherapy study as well as a Phase 1b combination study with an
anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal
antibody platform is comprised of a number of immune modulating
assets in research and preclinical development, including
BION-1301, an anti-APRIL antibody. Aduro is collaborating with
leading global pharmaceutical companies to expand its products and
technology platforms. For more information, please visit
www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, our technology platforms, plans,
and the potential for eventual regulatory approval of our product
candidates. In some cases, you can identify these statements by
forward-looking words such as “may,” “will,” “continue,”
“anticipate,” “intend,” “could,” “project,” “seek”, “expect” or the
negative or plural of these words or similar expressions.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results and events to differ materially from those anticipated,
including, but not limited to, our history of net operating losses
and uncertainty regarding our ability to achieve profitability, our
ability to develop and commercialize our product candidates, our
ability to use and expand our technology platforms to build a
pipeline of product candidates, our ability to obtain and maintain
regulatory approval of our product candidates, our inability to
operate in a competitive industry and compete successfully against
competitors that have greater resources than we do, our reliance on
third parties, and our ability to obtain and adequately protect
intellectual property rights for our product candidates. We
discuss many of these risks in greater detail under the heading
“Risk Factors” contained in our quarterly report on Form 10-Q for
the quarter ended September 30, 2017, which is on file with the
Securities and Exchange Commission. Any forward-looking statements
that we make in this press release speak only as of the date of
this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264
Media Contact: Susan Lehner 510 809 2137 press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2023 to Apr 2024